Budapest XII

• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B … Recruiting
  2022-503114-23-00 3 2023-12-19 Breast Cancer
• A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o … Recruiting
  2022-502193-16-00 5 2023-11-14 Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• Study of pre- and post-surgery treatment with IPH5201 and durvalumab in participants with lung cancer (MATISSE) Recruiting
  2023-507778-42-00 4 2023-03-08 Non-Small Cell Lung Cancer II, III
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin … Recruiting
  2023-505347-38-00 9 2022-06-13 B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl … Recruiting
  2023-506891-28-00 5 2022-05-02 The target population of interest in this study is participants with l
• Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced n … Recruiting
  2023-509283-14-00 1 2022-04-25 Advanced non-small cell lung cancer
• Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo … Recruiting
  2023-508963-58-00 4 2022-01-31 Symptomatic hypertrophic cardiomyopathy (HCM)
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C … Recruiting
  2024-515273-10-00 7 2021-10-19 Relapsed or refractory Multiple Myeloma (r/r MM)
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• Clinical trial to evaluate safety and effectiveness of APL-101 for the treatment of advanced MET expressing solid tumors, including Non-Smal … Recruiting
  2024-514542-37-00 9 2020-08-13 Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
• A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-00 … Recruiting
  2024-512606-25-00 7 2019-12-20 Advanced Solid Tumors
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Study to allow access to dabrafenib and/or trametinib for subjects that are benefiting from dabrafenib and/or trametinib treatment in a Nova … Recruiting
  2023-509318-13-00 6 2018-01-15 Multiple indications
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended recruitment
  2025-520520-17-00 5 2025-09-05 Heterozygous familial hypercholesterolaemia
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia

Showing 121–144 of 317 trials